Amendment: SEC Form SCHEDULE 13D/A filed by Tango Therapeutics Inc.
$TNGX
Biotechnology: Pharmaceutical Preparations
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)
|
Tango Therapeutics, Inc. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
87583X109 (CUSIP Number) |
Third Rock Ventures, LLC 201 Brookline Avenue, Suite 1401 Boston, MA, 02215 617-585-2000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
11/12/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 87583X109 |
| 1 |
Name of reporting person
Third Rock Ventures IV, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,374,574.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
6.97 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.
SCHEDULE 13D
|
| CUSIP No. | 87583X109 |
| 1 |
Name of reporting person
Third Rock Ventures GP IV, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,374,574.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
6.97 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.
SCHEDULE 13D
|
| CUSIP No. | 87583X109 |
| 1 |
Name of reporting person
TRV GP IV, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,374,574.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
6.97 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 4, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock | |
| (b) | Name of Issuer:
Tango Therapeutics, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
201 Brookline Avenue, Suite 901, Boston,
MASSACHUSETTS
, 02215. | |
Item 1 Comment:
This Amendment No. 2 (this "Amendment") amends and supplements the Schedule 13D (the "Schedule 13D") filed by the Reporting Persons with respect to the shares of common stock, $0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. (the "Company" or the "Issuer"). The transactions described in Item 5(c) resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Schedule 13D. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | As of November 11, 2025, TRV IV had shared voting and dispositive power with respect to 9,374,574 shares of the Issuer's Common Stock, constituting approximately 6.97% of the Issuer's outstanding Common Stock.
As of November 11, 2025, Third Rock Ventures GP IV, L.P. ("TRV GP IV"), as the general partner of TRV IV may be deemed to have shared voting and dispositive power with respect to all 9,374,574 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately of the Issuer's outstanding Common Stock.
As of November 11, 2025, TRV GP IV, LLC ("TRV GP IV LLC," and collectively with TRV IV and TRV GP IV, the "Reporting Persons"), as the general partner of TRV GP IV may be deemed to have shared voting and dispositive power with respect to all 9,374,574 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately 6.97% of the Issuer's outstanding Common Stock.
The percent of class was calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on Novemebr 4, 2025. | |
| (b) | Regarding the number of shares as to which such person has:
(i) sole power to vote or to direct the vote: See line 7 of cover sheets
(ii) shared power to vote or to direct the vote: See line 8 of cover sheets
(iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets.
(iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets | |
| (c) | Except as set forth in the table below, no transactions in the Common Stock were effected by the Reporting Persons during the 60-day period ended November 11, 2025.
Date Amount of Securities Price per Share Where and How Effected
TRV IV 9/16/2025 363,541 $7.04* Disposed in the Open Market
TRV IV 9/25/2025 500,000 $8.02* Disposed in the Open Market
TRV IV 10/23/2025 477,401 $10.15* Disposed in the Open Market
TRV IV 11/6/2025 1,500,000 $8.00* Disposed in the Open Market
TRV IV 11/10/2025 278,956 $8.00* Disposed in the Open Market
TRV IV 11/11/2025 721,044 $8.20* Disposed in the Open Market
TRV IV 11/12/2025 1,512,000 $8.20* Disposed in the Open Market
* The price reported is a weighted average price. These shares were sold in multiple transactions. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|